Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $30.20 USD
Change Today +0.26 / 0.87%
Volume 547.1K
CSII On Other Exchanges
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

cardiovascular systems inc (CSII) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - $41.28
52 Week Low
10/1/14 - $23.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cardiovascular systems inc (CSII) Related Bloomberg News

View More Bloomberg News

cardiovascular systems inc (CSII) Related Businessweek News

No Related Businessweek News Found

cardiovascular systems inc (CSII) Details

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and markets devices for the treatment of vascular diseases. Its products include catheter-based platforms, such as the Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. The company markets its products through direct sales force to hospitals and office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

479 Employees
Last Reported Date: 08/28/14
Founded in 1989

cardiovascular systems inc (CSII) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $330.7K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $305.4K
Chief Healthcare Policy Officer
Total Annual Compensation: $318.7K
Chief Administrative Officer, Compliance Offi...
Total Annual Compensation: $296.4K
Compensation as of Fiscal Year 2014.

cardiovascular systems inc (CSII) Key Developments

Cardiovascular Systems Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2015

Cardiovascular Systems Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported revenues of $47,004,000 compared to $34,945,000 a year ago. Loss from operations was $10,543,000 compared to $9,593,000 a year ago. Net loss was $10,656,000 or $0.34 per basic and diluted share compared to $9,712,000 or $0.32 per basic and diluted share a year ago. Adjusted LBITDA was $6,004,000 compared to $6,413,000 a year ago. The improvement was driven by a higher level of stock compensation expense. Net loss increased from the prior year primarily due to planned investments, including sales force expansion and coronary product commercialization. Cash usage in the quarter of $8 million included about $5 million of property and equipment primarily for new facility in Minnesota. For the nine months period, the company reported revenues of $133,090,000 compared to $97,048,000 a year ago. Loss from operations was $23,985,000 compared to $23,935,000 a year ago. Net loss was $24,153,000 or $0.77 per basic and diluted share compared to $25,662,000 or $0.94 per basic and diluted share a year ago. Adjusted LBITDA was $11,529,000 compared to $15,271,000 a year ago. For the fiscal 2015 fourth quarter ending June 30, 2015, the company anticipates revenue growth of 24% to 28% over the fourth quarter of fiscal 2014, to a range of $49.0 million to $50.5 million; gross profit as a percentage of revenues approximately 50 basis points higher than the third quarter of fiscal 2015. Net loss expects to be in the range of $9.0 million to $10.0 million, or loss per common share ranging from $0.28 to $0.31, assuming 31.8 million average shares outstanding.

Cardiovascular Systems Inc. Receives FDA Clearance for New Peripheral Diamondback Device

Cardiovascular Systems Inc. received FDA clearance for the new 4 French (4 Fr) 1.25 Solid Diamondback 360® Peripheral Orbital Atherectomy System (OAS) for the treatment of peripheral artery disease (PAD). Specifically, the clearance covers the company’s 145cm long: New 1.25mm Diamondback 360 Solid Crown, 4 Fr sheath compatible; and Modified 1.25mm Diamondback 360 Micro Crown, 4 Fr sheath compatible. CSI’s Diamondback Peripheral 145cm systems are available in two crown designs, the 1.25mm Solid Crown, and the 1.25mm Micro Crown. Both devices offer a smaller profile and a more flexible shaft for improved ease of use. As many as 18 million Americans, most over age 65, suffer from PAD, which is caused by plaque accumulation in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates. Moreover, approximately 25% of PAD cases will progress to critical limb ischemia (CLI), which is associated with complex occlusions in the tibial arteries (responsible for supplying blood flow to the lower legs and feet). It is estimated that up to 20% of these occlusions are unable to be treated from the traditional femoral artery access site. However, recent advancements in technology and techniques have made the use of retrograde tibiopedal access (where physicians achieve access through the arteries in the foot or ankle) more popular, thereby expanding the treatment options available for PAD patients. Millions of patients with PAD may benefit from treatment with orbital atherectomy utilizing the Stealth 360® and Diamondback 360 Peripheral Orbital Atherectomy Systems, minimally invasive catheter systems developed and manufactured by CSI. These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue "a critical factor in Cardiovascular Systems Inc. preventing reoccurrences. Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions. Stents are prone to fractures and high recurrence rates, and treatment of hard, calcified lesions often leads to vessel damage and suboptimal results.

Cardiovascular Systems Inc. to Report Q3, 2015 Results on Apr 29, 2015

Cardiovascular Systems Inc. announced that they will report Q3, 2015 results at 3:45 PM, Central Standard Time on Apr 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSII:US $30.20 USD +0.26

CSII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $16.86 USD +0.19
CryoLife Inc $10.18 USD +0.09
LeMaitre Vascular Inc $9.42 USD +0.44
Merit Medical Systems Inc $19.92 USD +0.04
Spectranetics Corp/The $26.01 USD +1.68
View Industry Companies

Industry Analysis


Industry Average

Valuation CSII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOVASCULAR SYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at